home / stock / gern / gern news


GERN News and Press, Geron Corporation From 06/07/24

Stock Information

Company Name: Geron Corporation
Stock Symbol: GERN
Market: NASDAQ
Website: geron.com

Menu

GERN GERN Quote GERN Short GERN News GERN Articles GERN Message Board
Get GERN Alerts

News, Short Squeeze, Breakout and More Instantly...

GERN - US Companies Moving the Markets, Morning edition
Fri, Jun 07, 2024 as of 10.00 am ET

A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 37.2% to $0.7466 on volume of 94,759,512 shares GameStop Corporation (GME) rose 0.0% to $46.5702 on volume of 64,189,668 shares Trinity Place Holdings Inc. (TPHS) rose 126.9% to $0....

GERN - 3 stocks to watch on Friday: GME, GERN, and more

2024-06-07 09:00:40 ET More on related stocks: Roaring Kitty Sparks GameStop Surge With $100M Bet: Analysis And Insights GameStop Stock: Disconnected From Fundamentals GameStop: 'Roaring Kitty' Is Back, Nearly All-In With $175 Million Bet Lyft attracts analys...

GERN - Geron lead asset approved in the U.S. for blood cancer

2024-06-06 22:31:45 ET More on Geron Geron Corporation: A High-Risk Deal With A Good Chance Of Success Geron Corporation (GERN) Q1 2024 Earnings Call Transcript Geron: FDA PDUFA Review With Continued Imetelstat Advancement Geron GAAP EPS of -$0.09 beats by $0...

GERN - Geron Announces FDA Approval of RYTELO(TM) (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia

Approval across ESA ineligible and ESA relapsed/refractory patients with LR-MDS with transfusion-dependent anemia, regardless of ring sideroblast (RS) status Durable and sustained red blood cell transfusion independence, increases in hemoglobin levels and reduction in transfusion burden o...

GERN - Geron Corporation: A High-Risk Deal With A Good Chance Of Success

2024-05-23 17:49:01 ET Summary Geron Corporation's unique product, Imetelstat, could potentially bring real benefits to hematological diseases with a Total Addressable Market value of $7 billion by 2031. Clinical studies have shown statistical evidence supporting the effectiveness...

GERN - Geron (GERN) Q1 2024 Earnings Call Transcript

2024-05-03 00:30:12 ET Image source: The Motley Fool. Geron (NASDAQ: GERN) Q1 2024 Earnings Call May 02, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Geron (GERN) Q1 2024 Earnings Call Transcript

GERN - Geron Corporation (GERN) Q1 2024 Earnings Call Transcript

2024-05-02 12:32:10 ET Geron Corporation (GERN) Q1 2024 Earnings Conference Call May 2, 2024 8:00 am ET Corporate Participants Aron Feingold - VP of IR and Corporate Communications John Scarlett - Chairman, President and Chief Executive Officer Faye Feller - Exec...

GERN - Geron GAAP EPS of -$0.09 beats by $0.01

2024-05-02 07:08:56 ET More on Geron Geron: FDA PDUFA Review With Continued Imetelstat Advancement Considering The Merits Of A Gamble On Geron Corporation Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy Geron Q1 2024 Earnings Previe...

GERN - Expected US Company Earnings on Thursday, May 2nd, 2024

Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...

GERN - Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights

June 16, 2024 PDUFA date for imetelstat NDA for the treatment of transfusion-dependent anemia in adult patients with lower-risk MDS Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelsta...

Previous 10 Next 10